CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

CSL-Vifor-Travere

More Like This

PR Newswire associated0

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

PR Newswire associated0

Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function

Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab

STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU

Business Wire logo

Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy